SPY308.08+2.53 0.83%
DIA257.85+2.58 1.01%
IXIC9,608.38+56.33 0.59%

Credit Suisse Maintains Neutral on Aimmune Therapeutics, Lowers Price Target to $19

Credit Suisse analyst Evan Seigerman maintains Aimmune Therapeutics (NASDAQ:AIMT) with a Neutral and lowers the price target from $29 to $19.

Benzinga · 05/13/2020 12:14

Credit Suisse analyst Evan Seigerman maintains Aimmune Therapeutics (NASDAQ:AIMT) with a Neutral and lowers the price target from $29 to $19.